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Summary 
Robert F. Furchgott, pharmacologist and joint winner of the Nobel Prize for Medicine 
or Physiology (1998) died on the 12th of May 2009 aged 92. By unlocking the 
astonishingly diverse biological actions of nitric oxide, Furchgott leaves behind a rich 
legacy that has both revolutionised our understanding of human physiology and 
stimulated new and exciting opportunities for drug development in a wide range of 
pathological conditions. In this article, William Martin, who worked with Furchgott 
for two years (1983-1985) following the exciting discovery of endothelium-derived 
relaxing factor (EDRF)/nitric oxide, pays tribute to his close friend and colleague.  
 
Introduction 
May 12th 2009 saw the passing of Robert F. Furchgott (Bob to his friends and 
colleagues), perhaps the most accomplished and revered pharmacologist of his 
generation. There can be few in our discipline whose work has pervaded so many 
facets of biology and medicine and led to such a fundamental reappraisal of our 
understanding. Indeed, the awarding of the ultimate accolade, the Nobel Prize for 
Medicine or Physiology, to Furchgott (together with Ferid Murad and Louis Ignarro) 
in 1998, reflects the importance and world-wide impact of the discovery that nitric 
oxide plays a vital role in health and disease. There are many resources available to 
those seeking a comprehensive account of Furchgott’s life and work as a scientist, but 
two of the most authoritative can be found on the Nobel website. The first is 
Furchgott’s autobiography  
(http://nobelprize.org/nobel_prizes/medicine/laureates/1998/furchgott-autobio.html) 
in which he recounts his entry into science, his early work on receptor theory, 
including his introduction of the concept of receptor reserve and a method for 
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estimating the equilibrium dissociation constant for an agonist by using an irreversible 
antagonist. It also highlights his work on adrenergic mechanisms and the 
characterisation of receptors on blood vessels. In fact, these accomplishments alone 
would be regarded by most as a worthy life’s work. He makes no mention here, 
however, of the discovery of endothelium-derived relaxing factor (EDRF)/nitric oxide 
– he reserves his personal account of this, the most celebrated of all his contributions, 
for the text of his Nobel lecture 
(http://nobelprize.org/nobel_prizes/medicine/laureates/1998/furchgott-lecture.html). 
There is surely no more insightful a way to learn of the story of nitric oxide, the 
events and the personalities involved, than by reading a truly masterful account of it 
in the words of the great man himself. 
 
Thus, Furchgott leaves behind so rich a legacy to his discipline that to do justice to it 
in a short tribute is an impossible task. Instead, I give here a personal reflection on the 
two super-charged years (1983-1985) I spent researching with him in his laboratory at 
the Downstate Medical Center in Brooklyn, New York. Although fully aware of just 
how privileged I was to get the opportunity to work with one of the world’s greatest 
scientists who had just made the most important discovery of his career, the 
experience was to prove so much more. Getting to know Furchgott, a man of great 
sensitivity, humility, kind heartedness and warmth, who was destined to become a 
dear friend, added a most pleasant personal dimension to our interactions. 
 
The discovery of EDRF 
I first encountered Bob Furchgott in 1980 at Paul Vanhoutte’s symposium on 
Mechanisms of Vasodilatation in Antwerp. As this was the year he published his now 
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legendary paper in Nature (Furchgott & Zawadzki, 1980), it is not difficult to imagine 
the raw excitement of this time. The electric atmosphere generated by Furchgott as he 
recounted his discovery of EDRF and the process of endothelium-dependent 
vasodilatation while the audience sat in stunned silence was surely one of the most 
inspiring moments in science. The importance of this was particularly acute to me, as 
I had just completed my PhD on non-adrenergic, non-cholinergic (NANC) inhibitory 
transmission with John Gillespie and had recently moved to postdoctoral position 
with John Gordon and Jeremy Pearson at the Babraham Institute in Cambridge, where 
they directed one of the few laboratories in the UK investigating vascular endothelial 
cell function. 
 
Linking EDRF with NANC inhibitory transmission 
As my own interest in endothelial cells developed and my postdoctoral funding drew 
to an end, I began communicating with Furchgott in the hope of securing a post in his 
lab. I drew to his attention the striking parallels between the work of John Gillespie’s 
lab in Glasgow on the unidentified NANC inhibitory transmitter in the rat 
anococcygeus muscle (Gillespie, 1972) and his own work on EDRF. I explained that 
John Gillespie had assigned to me the task of trying to extract the NANC transmitter 
from the bovine retractor penis muscle (BRP), an anatomical extension of the 
anococcygeus, following publication of an abstract from Ambache’s lab (Ambache et 
al., 1975). Like Ambache, we succeed in extracting from the BRP a novel, labile 
smooth muscle relaxant that mimicked the action of its inhibitory nerves. We gave 
this the name “inhibitory factor”, and went on to characterise some of its properties 
(Gillespie & Martin, 1980; Gillespie et al., 1981). Its most unusual feature was that it 
was active if extracted in weak acid, but inactive if extracted at neutral pH; a brief 
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exposure of the latter to acid pH, optimum at pH 2, however, transformed it to its 
active form. These properties struck a chord with Furchgott, because it reminded him 
of an accidental finding he made in his own laboratory several years before, when 
sodium nitrite had been prepared in error in an acidic rather than a neutral solution 
and had transformed the weak long-lasting relaxant into a more potent ephemeral 
agent. As will be seen later, these observations contributed to his eventual conclusion 
that EDRF and the inhibitory factor were nitric oxide. The other major aspect that 
excited Furchgott was that the late Anne Bowman, who joined Gillespie’s lab in the 
last year of my PhD studies, showed that inhibitory factor was a powerful vasodilator 
in vitro (Bowman et al., 1981). Surprisingly however, inhibitory factor had absolutely 
no effect on the blood pressure of the anaesthetised rat. In her own characteristically 
tenacious manner, Anne strove to solve this puzzling anomaly. Convinced it was 
blood that was inactivating inhibitory factor, Anne invited me to join her in one last 
experiment before I left Glasgow. She harvested some whole heparinised blood, spun 
an aliquot to obtain erythrocyte and plasma fractions, and mixed each of them with 
BRP extract, which I then bioassayed. Anne’s conviction had been correct, blood was 
indeed able to block the actions of inhibitory factor, and the agent responsible resided 
in the erythrocytes but not the plasma (Bowman et al., 1981). Of course, later work by 
Anne, John Gillespie and David Pollock established that it was haemoglobin that 
inactivated inhibitory factor, and even more importantly, that it also blocked in a 
highly selective manner NANC inhibitory transmission in the BRP (Bowman et al., 
1982; Bowman & Gillespie, 1982). Thus, haemoglobin, which we now know interacts 
rapidly with nitric oxide, resulting in the formation of nitrate and methaemoglobin, 
became established as the first useful tool to modulate the activity of the NANC 
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inhibitory nerves. Inspired by these parallels to his own work on EDRF, Furchgott 
required no further persuasion to allow me to join his laboratory. 
 
I arrived in New York at a particularly bleak time for Furchgott; his wife Lenore was 
in a hospice and died some two weeks later. In spite of his difficulties at this time, 
Furchgott went out of his way to make me, my wife Anne and son Steve, feel very 
welcome and provided all sorts of practical help in getting settled in our new 
environment. Over the next few months we grew very close and informally adopted 
him into our family. Thursday became our relaxed beer and pizza night and we often 
had him over for a proper dinner at the weekend too. I would like to think that as our 
friendship grew that we helped him through those dark days following the loss of his 
wife. We shared so much both professionally and socially in those two terrific years. 
Bob introduced us to the delights of New York City, Long Island and to sailing and 
fishing in Long Island Sound. In turn, we took him to our home in Glasgow in the 
summer of 1984 and toured the mountains, lochs and castles of the Scottish 
Highlands. Such were the beginnings of a long and deep personal friendship and 
professional association. 
 
Haemoglobin inactivates EDRF 
On my arrival in the Furchgott laboratory, it was obvious that we, together with our 
colleagues Gina Villani and Desingaro Jothianandan, should investigate whether 
haemoglobin had the same inhibitory effects on endothelium-dependent relaxation as 
it did on NANC inhibitory transmission. Indeed it did, and in a spectacularly selective 
manner that permitted the endothelium-independent relaxant action of isoprenaline to 
operate entirely unhindered (Martin et al., 1985a; Martin et al., 1985b). From that 
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point on our conviction grew that the identities of EDRF and the NANC inhibitory 
transmitter were linked. Indeed, a rapid series of events in different laboratories 
around the world confirmed this to be true. The next important lead came from 
Murad’s lab which showed that endothelium-dependent relaxation of the rat aorta was 
associated with an elevation in smooth muscle cGMP content (Rapoport & Murad, 
1983), through an action on soluble guanylate cyclase. This was the same pathway 
that Murad’s group had shown some years earlier underpinned the relaxant actions of 
the nitrovasodilators, nitroprusside and glyceryl trinitrate, and even nitric oxide itself 
(Katsuki et al., 1977). Thus, the effector pathway and second messenger system used 
by EDRF to promote smooth muscle relaxation was established. This was quickly 
followed by a paper from the Glasgow lab showing that relaxation of the BRP by the 
NANC inhibitory nerves or by inhibitory factor was also associated with a rise in 
cGMP content and, furthermore, that haemoglobin abolished all of these actions 
(Bowman & Drummond, 1984). In the Furchgott lab we demonstrated that 
haemoglobin also abolished the rise in cyclic GMP induced by EDRF in the rabbit 
aorta (Martin et al., 1985b). Furthermore, as is often the case with the introduction of 
a new pharmacological tool, haemoglobin provided a host of other new and 
unexpected insights. For example, although it had no effect on the tone of rat or rabbit 
uncontracted aortic rings, in submaximally contracted tissues, haemoglobin 
augmented tone if the endothelium was present but not if it had been removed (Martin 
et al., 1985b; Martin et al., 1986b). Interestingly, when haemoglobin produced this 
enhancement of vasoconstrictor tone, it lowered the cGMP content of the aortic rings, 
consistent with the earlier observation in Murad’s lab that the resting level of this 
cyclic nucleotide was lower in endothelium-denuded than in endothelium-containing 
rings (Rapoport & Murad, 1983). Thus, the use of haemoglobin in Furchgott’s lab 
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provided the first evidence that a basal (unstimulated) release of EDRF suppressed 
vasoconstrictor tone in the vasculature, and this was, of course, confirmed later upon 
the introduction of inhibitors of nitric oxide synthase (Rees et al., 1989; Moore et al., 
1990; Rees et al., 1990). The physiological and pathological implications of the 
ability of haemoglobin to inhibit EDRF were not lost on Furchgott; he concluded that 
EDRF must be a local autacoid and not a circulating hormone, and that haemoglobin 
might be responsible for the profound vasospasm associated with haemorrhage, in 
particular that following haemorrhagic stroke (Furchgott et al., 1985a). 
 
Shedding more light   
In parallel with the work on haemoglobin on EDRF, Furchgott persuaded others in the 
lab, principally Desingaro Jothianandan, to pursue his other major discovery and great 
passion, the phenomenon of photorelaxation (by UV light). This he first observed 
when a cloud lifted and sunlight irradiated his tissue baths contain rabbit aortic strips 
(Furchgott et al., 1961). Intriguingly, photorelaxation of the rabbit aorta did not 
require the presence of the endothelium, but as with relaxation induced by EDRF, it 
took place in association with an elevation of smooth muscle cGMP content, and 
these actions were virtually abolished by haemoglobin (Furchgott et al., 1984; 
Furchgott et al., 1985b). As a consequence, Furchgott became convinced that the 
“photo-activated relaxant factor” was linked in some way to EDRF and the inhibitory 
factor from BRP. We know now of course that photorelaxation proceeds through the 
photolytic decomposition of smooth muscle S-nitrosothiols and the resultant 
liberation of nitric oxide (Megson et al., 2000; Ng et al., 2007). Thus evolved yet 
another strand in the tangled web that led Furchgott ultimately to nitric oxide 
(Furchgott, 1988). 
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 Information from phosphodiesterase (PDE) isoform 5 inhibition 
In another development at that time, the Glasgow group showed that the selective 
PDE 5 inhibitor, M&B 22948 (zaprinast), produced a powerful enhancement of 
NANC inhibitory transmission and associated elevation of cGMP in the BRP muscle 
(Bowman & Drummond, 1984). Shortly thereafter, the Furchgott lab demonstrated 
similar findings in rat and rabbit aorta, whereby M&B 22948 and the non-selective 
PDE inhibitors, papaverine and isobutylmethylxanthine, produced endothelium-
dependent relaxation, not through the stimulated release of EDRF, but by potentiation 
of basal EDRF activity resulting from the slowed hydrolysis of cGMP (Martin et al., 
1986a). This was the extent of Furchgott’s involvement with PDE 5 inhibitors. 
Contrary to what has been portrayed in the popular media, Furchgott never worked on 
or was involved in the development of Pfizer’s anti-impotence treatment, Viagra 
(sildenafil). It is therefore likely that certain sensationalist headlines in the media 
reporting his death, such as “US Viagra scientist dies at 92”, “Viagra developer 
Furchgott dies at 92”, have caused some distress to his family and close friends. Yes, 
he helped pave the way for its development, but had no involvement with Pfizer. It is 
perhaps a sad reflection on some of our major news agencies that they failed to report 
the true nature of his life’s work and its importance. 
 
The final piece of the puzzle 
With the expiry of both my funding and visa, my involvement in the Furchgott lab 
ended and I returned to the UK with world events taking place at an ever increasing 
pace. Independent reports from the laboratories of Vanhoutte and Moncada 
demonstrated that superoxide anion rapidly destroyed EDRF, while superoxide 
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dismutase (SOD) potentiated and prolonged its actions (Rubanyi & Vanhoutte, 1986; 
Gryglewski et al., 1986). This proved to be the final piece in the puzzle for Furchgott. 
He subsequently reported at the 1986 symposium on Mechanisms of Vasodilatation 
that superoxide anion and SOD had identical effects on the biological activities of 
EDRF and nitric oxide, the latter generated using acidified nitrite (Furchgott, 1988). 
More importantly, he reviewed the literature to-date and on the basis of similar 
physical, chemical and pharmacological properties concluded that both EDRF and the 
inhibitory factor extracted from the BRP muscle were nitric oxide. In fact, at the same 
meeting Ignarro also proposed that EDRF was nitric oxide on the basis of spectral 
data showing their identical interactions with haemoglobin (Ignarro et al., 1988). It is 
somewhat unfortunate that a dispute with the publisher delayed the publication of 
these two reports, but with the major players in the field assembled at the symposium, 
the genie was out of the bottle – EDRF was looking increasingly like nitric oxide. 
 
Confirmation that EDRF and the NANC inhibitory transmitter are nitric oxide 
We largely have the Moncada group to thank for completing the story; using a 
cascade bioassay system linked to a chemiluminescence detector they proved not only 
that nitric oxide was indeed released from endothelial cells, but it was released in 
amounts that accounted fully for the biological actions of EDRF (Palmer et al., 1987). 
In an accompanying Commentary in Nature, Vanhoutte announced “The end of the 
quest?” (Vanhoutte, 1987). Yes, this particular quest had indeed ended, but another 
had immediately begun – that to identify the precursor and synthetic pathway from 
which nitric oxide was derived. Soon thereafter the Moncada group revealed that 
nitric oxide was synthesised from a guanidino nitrogen of L-arginine (Palmer et al., 
1988) and that an NG-substituted analogue, NG-monomethyl-L-arginine (L-NMMA), 
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which we now recognise as an inhibitor of nitric oxide synthase, blocked in a 
competitive and stereo-specific manner, both the release of nitric oxide from rabbit 
aorta and the associated EDRF-mediated relaxation  (Rees et al., 1989). It was a 
satisfying end of the quest too for John Gillespie who had pursued the identity of the 
NANC inhibitory transmitter for so many years. He retired soon thereafter, content in 
the knowledge that he, simultaneously with two other groups, had identified the 
NANC transmitter too as nitric oxide (Li & Rand, 1989; Gillespie et al., 1989; 
Ramagopal & Leighton, 1989). Thus, the L-arginine-nitric oxide pathway had become 
firmly established as a vital signalling system in biology. 
 
The lasting legacy of Furchgott 
Furchgott knew in 1980 when he first published on the phenomenon of endothelium-
dependent vasodilatation that he was on to something big. Even he, however, could 
never have contemplated the scale of what he had started. The account above was 
merely the beginning, the field rapidly expanding thereafter into man, elucidating the 
astonishingly diverse roles played by nitric oxide in human physiology and disease.  
Those wishing to keep up with work that continues to develop from Furchgott’s 
legacy may find the Journal’s new “Virtual Endothelial Issue” to be a valuable 
resource (http://www.brjpharmacol.org/view/0/VirtualIssues.html). In addition to 
nitric oxide, topics highlighted here include, signalling by other endothelium-derived 
mediators such as endothelium-derived hyperpolarizing factor (EDHF) (Michel et al., 
2008; Garland & Dora, 2008), nitroxyl anion (Martin, 2009; Andrews et al., 2009), 
endothelin (Farhat et al., 2008; de Andrade et al., 2009) and prostanoid contractile 
factors (Félétou et al., 2009).  
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Furchgott’s legacy extended yet wider still, sparking investigations into the functions 
of nitric oxide throughout the animal kingdom and in plants. From a pharmacologist’s 
perspective, the nitric oxide saga has been an exceedingly fruitful area for 
therapeutics; it uncovered the mechanism of action of the nitrovasodilators that had 
hitherto been employed empirically for over 100 years to treat angina, and set the 
scene for the development of a vast array of new drug treatments. Present examples 
include nitric oxide itself for respiratory failure in premature infants and in adult 
respiratory distress syndrome, and PDE 5 inhibitors for the treatment of impotence 
and, more recently, pulmonary hypertension. Future promise is widely anticipated in a 
number of areas, including the development of selective inhibitors of inducible nitric 
oxide synthase for septic shock and a host of other inflammatory and immune 
diseases, selective inhibitors of neuronal nitric oxide synthase for the treatment of 
stroke and other neurological pathologies, and nitric oxide-releasing non-steroidal 
anti-inflammatory drugs to limit the gastric bleeding and ulceration commonly 
encountered with NSAIDs. In short, Furchgott’s legacy shows no limits and looks set 
to expand for decades to come. He was a brilliant scientist and greatly admired 
character who changed the world – but fortunately the world did not change him – he 
remained ever humble in the face of growing fame and celebrity. The world mourns 
the loss of one of the great gentlemen of science. 
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